PAO Group, Inc. released preview of the company's plan to launch CBD Nutraceuticals line of products. PAOG's CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method. Starting in the fourth quarter of 2021, PAOG plans to begin the introduction of three CBD Nutraceuticals. The first CBD Nutraceutical under development will sell under the name CBD RELAX-RX targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The second CBD Nutraceutical under development will be derived from PAOG's ongoing COPD research targeting the COPD treatment market separately from the pharmaceutical market also targeting COPD treatment. The third CBD Nutraceutical is being developed in partnership with the EVERx CBD Sports Water Brand owned by Puration, Inc. and will target the sports nutrition market. PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. as a copacker and North American Cannabis Holdings, Inc. as a distributor.